| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c63fcd992f4eb4cc1c1938bfb0c01ae0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P23-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate |
2014-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c220dfc27d840c9523b524021b81adc2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fec15935032e2c5f07b397bdbae11d6a |
| publicationDate |
2019-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TR-201903411-T4 |
| titleOfInvention |
Neosaxytoxin combination formulations for long-term local anesthesia. |
| abstract |
Because each of the zone I sodium channel blockers has specific activity and cannot be used to extrapolate the same effective dosage for another zone I sodium channel blocker, neosaxytoxin ("NeoSTX") and epinephrine alone or in combination with epinephrine for pain relief in humans for two to three days. Studies have been conducted to determine bupivacaine dosages. Bupivacaine-NeoSTX combinations provide more reliable blockade and longer duration blockade compared to NeoSTX alone. NeoSTX-bupivacaine-epinephrine triple combination provides longer duration local anesthesia compared to NeoSTX-bupivacaine dual combination. Adding epinephrine to this NeoSTX-bupivacaine combination significantly prolongs the duration of complete blockade against mechanical stimulus. These results led to the development of special combination dosage formulations. |
| priorityDate |
2013-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |